Rasheda Ali, Daughter of Muhammad Ali Visits BrainStorm Company Laboratories
Rasheda Ali, Daughter of Legendary Muhammad Ali and Advisory Board Member of BrainStorm, Visits Company Laboratories and Clinical Trials Site at Hadassah Medical Center in Jerusalem, Israel 08/13 08:35 AM
NEW YORK & PETACH TIKVAH, Israel–(BUSINESS WIRE)– BrainStorm Cell Therapeutics (BCLI:$0.2589,$0.0069,2.74%) , a leading developer of adult stem cell technologies and CNS therapeutics, announced that Rasheda Ali Walsh, daughter of the legendary Muhammad Ali, visited the Company’s laboratories as well as its cleanrooms at Hadassah Medical Center, where she received a briefing on the company’s clinical trial conducted there. Ms. Ali Walsh, an internationally known advocate for promoting research and awareness of neurodegenerative diseases, is a member of the Advisory Board of BrainStorm.
BrainStorm’s President, Mr. Chaim Lebovits, and CEO Dr. Adrian Harel accompanied Ms. Ali Walsh for a meeting with Prof. Dimitrios Karussis, Principal Investigator of the Company’s ongoing Phase I/II clinical trial at Hadassah, and Prof. Tamir Ben-Hur, Head of the Neurology Department. The group discussed the latest innovative treatments for neurodegenerative diseases and BrainStorm’s leading role in this area.
“Having heard so much about the recent positive interim safety report and the outstanding progress being made by BrainStorm at Hadassah, I felt the need to actually meet the team in person,” commented Ms. Ali. “The amazing work being done here gives a ray of hope to patients and families worldwide that autologous stem cell transplants may be the answer they’ve been waiting for to overcome neurodegenerative diseases.”
According to Dr. Adrian Harel, BrainStorm’s CEO, “The support and encouragement by world-renowned individuals like Rasheda Ali is important for increasing awareness of the need for a cure for debilitating neurodegenerative diseases. We are hopeful that this awareness will lead to more widespread efforts by governments and health organizations worldwide to fund research in this area and provide assistance to patients and their families.”
About BrainStorm Cell Therapeutics, Inc. (BCLI:$0.2589,$0.0069,2.74%)
BrainStorm Cell Therapeutics Inc. (BCLI:$0.2589,$0.0069,2.74%) is a biotechnology company engaged in the development of adult stem cell therapeutic products derived from autologous bone marrow cells and intended for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel-Aviv University. For more information, visit the company’s website at www.brainstorm-cell.com.
Safe Harbor Statement
Statements in this announcement other than historical data and information constitute “forward-looking statements” and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.’s (BCLI:$0.2589,$0.0069,2.74%) actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”, “likely”, “believe”, “plan”, “estimate”, “predict”, “potential”,and similar terms and phrases are intended to identify these forward-looking statements.The potential risks and uncertainties include, without limitation, risks associated with BrainStorm’s limited operating history, history of losses; minimal working capital, dependence on its license to Ramot’s technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements.The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
Source: BrainStorm Cell Therapeutics (BCLI:$0.2589,$0.0069,2.74%)
Get more news on:SYMBOLS: BCLINEWS TYPE: SECTORS: Consumer Discretionary, Media, Health Care, Pharmaceuticals